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Background. MicroRNAs are small RNA molecules that regulate the expression of certain genes through interaction with mRNA
targets and are mainly involved in human cancer. This study was conducted to make the network of miRNAs-mRNAs interactions
in pancreatic cancer as the fourth leading cause of cancer death. Methods. 56 miRNAs that were exclusively expressed and 1176
genes that were downregulated or silenced in pancreas cancer were extracted from beforehand investigations. MiRNA–mRNA
interactions data analysis and related networks were explored usingMAGIA tool and Cytoscape 3 software. Functional annotations
of candidate genes in pancreatic cancer were identified by DAVID annotation tool. Results.This network is made of 217 nodes for
mRNA, 15 nodes for miRNA, and 241 edges that show 241 regulations between 15 miRNAs and 217 target genes. The miR-24 was
the most significantly powerful miRNA that regulated series of important genes. ACVR2B, GFRA1, and MTHFR were significant
target genes were that downregulated. Conclusion. Although the collected previous data seems to be a treasure trove, there was no
study simultaneous to analysis ofmiRNAs andmRNAs interaction.Network ofmiRNA-mRNA interactionswill help to corroborate
experimental remarks and could be used to refine miRNA target predictions for developing new therapeutic approaches.
1. Introduction
Pancreatic cancer has introduced itself as one of the top
five causes of cancer mortality. Although many efforts have
been attempted, the prognosis is still not desirable in which
surgical resection has been remained as the last choice for
the patients with advanced stage of disease [1]. It is worthy
of mention that even surgery has not made a great step in
mortality (improving 5-year survival rates from <4% if left
untreated to 25–30% after resection) [2]. As seen in other can-
cers, pancreatic cancer also occurs due to genetic alterations
and disturbances of gene expression [3]. One of regulatory-
genetic factors that have been identified in the past decade is
MicroRNAs (miRNAs).ThemiRNAs with 20–22 nucleotides
(nt) in length are a group of small noncoding RNAmolecules
with considerate function in posttranscriptional phase [4].
Modulation of apoptosis and expression of genes involved
in invasive behavior indicate the role of miRNAs in cancer.
Depending on the cell, tissue, and disease type, the expression
pattern of miRNAs could be different.
Today, it has been proved that deregulation in expression
of miRNAs has important role in the pathogenesis of genetic
and multifactorial cancers, as well as pancreatic cancer [5,
6]. Because the majority of human protein-coding genes
could be regulated by miRNAs, equally it was assumed
that miRNAs could have several target genes [7] though
miRNAs are apt to downregulate target mRNAs [8]. These
findings suggested that nearly more than one-third of human
genes are regulated by miRNAs through various silencing
pathways. Bearing in mind complex gene regulatory net-
works in biological systems, many scientific efforts have
been devoted to draw “the big picture” in miRNA-mRNA
interactions using the combination of experimental methods
and computational approaches. Most often disregulation of
miRNAs has reflected the pathophysiology of many can-
cers such as liver, prostate, and ovarian [9–11]. Moreover,
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molecular disregulation of miRNAs is believed to play major
roles in etiology of pancreatic cancer or be a consequence
of tumor formation that could be used as a biomarker for
tumor detection. Indeed expression of miRNAs correlated
with outcome in pancreatic cancer patients [12–15]. Recog-
nizing mRNAs regulated by miRNAs will help us for better
understanding of biological roles of miRNAs [16]. Although
the collected previous data seem to be a treasure trove, a
large portion of data is false-positive or insignificant. Many
computational methods have been developed to resolve this
problem to extract precise results. In this way, researches
on miRNAs-mRNAs interactions can lead us to pathways
from their identification to their functional assignment in
system biology. One motivation of systems biology research
is to understand gene functions and up-to-date structural and
functional annotations of genes [17, 18].
Pancreatic cancer is often diagnosed at a late stage and
surgical resection, if possible, is too difficult. Recognizing
early diagnosis biomarkers and molecular targets therapy
need to discover that was one important aim in experimental
studies [19, 20]. Furthermore, investigation of miRNAs-
mRNAs interactions in this cancer would be new approach to
gaining insight into complex biological processes not only for
brighter understanding of pancreatic cancer etiology but also
for designing newprognostic anddiagnostic strategies. In this
study, we performed a number of available software programs
for the purpose of construct of most efficient miRNA-mRNA
network analysis and visualization.
2. Methods
2.1. Search Studies and Datasets. PC-related miRNAs were
collected from miR2Disease base (http://www.mir2disease.
org/) database and also from the relevant literature. There
were a total of 64 pancreatic cancer miRNAs, in which, 8
miRNAs were downregulated and 56 miRNAs upregulated
(Table 1). Overall upregulated miRNAs which have been
described as oncogenes were selected for miRNA-mRNA
network analysis. The same strategy was performed for
mRNA expression pattern in PC. Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo), ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/), Stanford Microarray
Database (http://smd.princeton.edu/), and PubMed (http://
www.ncbi.nlm.nih.gov/pubmed) are comprehensive data-
bases for gene expression.
2.2. miRNA-mRNA Interaction Analysis. In this study, infor-
mation of mRNAs and miRNAs expression profiles retrieved
from different molecular methods; therefore we integrated
the data of miRNA and gene expression as not matched
samples byMAGIA tool (http://gencomp.bio.unipd.it/magia)
because matched data (samples have been produced in a
lab) were not available. Not matched data analysis option
in MAGIA tool is functional for samples in public database.
The data collection and processing give rise to two matrices,
for miRNAs and genes. Each matrix includes two classes of
samples (T for tumor and N for normal), for the miRNA and
gene matrices. The meta-analysis separately considers each
matrix to identify expression profiles significantly variable
among classes and integrate results with target predictions.
Note that expressionmatricesmust be tab-delimited text files;
the first row must contain sample names; the first column
must contain gene/miRNA IDs.
2.3. Integrative Analysis withNotMatched ExpressionMatrices
in Multistep Procedure
(1) We selected ID type (RefSeq) and “meta-analysis”
from the list of available methods for the integrated
analysis. MAGIA will calculate LIMMA 𝑃 values of
differential expression, which are then combined by
using the inverse chi-square distribution to identify
oppositely variable miRNA-gene pairs.
(2) Select a target prediction algorithm (miRanda, PITA,
and TargetScan) or a combination thereof. In this
study to ensure more, RefSeq ID and the intersection
of all three algorithms were used.
(3) Upload miRNAs and genes expression matrices.
(4) Finally, construction of network was performed via
the sequence complementarity between miRNA and
mRNA. Functional enrichment analysis was directly
uploaded, with corresponding settings on the DAVID
page. Moreover for network visualization a text file
was imported in Cytoscape software. The Evolution-
ary Trace Annotation (ETA)method in the Cytoscape
network visualization environment was carried out
for predicting the functional associations among
miRNAs and mRNAs [31]. This software supports the
visual features of nodes and edges, such as shape,
color, and size. In this network length of edges are
proportional to the log 𝑃 value, therefore genes that
are located on the farther representing by smaller
amount of 𝑃 value.
3. Gene Ontology and Pathway Analysis
The Sequence Retrieval System GeneDecks
(http://www.genecards.org/genedecks) that are a novel
analysis tool for transcriptome analyses and comprise
the largest databases of genes were used to establish the
targeted gene lists. Furthermore, DAVID Bioinformatics
Resources 6.7 (http://david.abcc.ncifcrf.gov/) were used for
understanding the biological meaning behind large lists of
genes, to obtain gene ontology and pathway information for
significant downregulated target genes in pancreatic cancer.
The important functions and biological roles of target genes
and their association with pancreatic cancer were assessed
by MALACARD server (http://www.malacards.org/).
4. Results
4.1. miRNAs and mRNA Expression Profiling. Overall 64
pancreatic cancer miRNAs, in which 8 miRNAs were down-
regulated and 56 miRNAs upregulated, have been identified
from databases. The 8 downregulated miRNAs were not
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Table 1: Designated studies for expression profile of microRNAs in pancreatic cancer.
Number References Detection method microRNAs
1 [21] Northern blot, qRT-PCR
hsa-let-7f-1, has-let-7d, miR-21, miR-212, miR-16-1, miR-424, miR-92-1, miR-107,
miR-181c, miR-15b, miR-155, miR-24-1, miR-24-2, miR-301, miR-376a, miR-181a, miR-221,
miR-100, and miR-125-1
2 [22] Microarray
miR-205, miR-99a, miR-21, miR-210, miR-213, miR-107, miR-10a, miR-10b, miR-181b-1,
miR-181b-2, miR-181c, miR-181d, miR-143, miR-199a-1, miR-199a-2, miR-155, miR-222,
miR-223, miR-23a, miR-23b, miR-181a, miR-220, miR-221, miR-100-1, miR-100-2,
miR-103-2, miR-125a, miR-125b-1, miR-146a, and miR-127
3 [6] Microarray
miR-20a, miR-21, miR-214, miR-92-2, miR-107, miR-128b, miR-181b-1, miR-199a-1,
miR-223, miR-24-1, miR-24-2, miR-25, miR-29b-2, miR-30c, miR-32, miR-17-5p,
miR-221, miR-106a, miR-146a, and miR-191
4 [23] Northern blot, qRT-PCR miR-21
5 [5] Northern blot, qRT-PCR miR-21, miR-107, and miR-103
6 [24] Northern blot, qRT-PCR miR-155
7 [25] Northern blot, qRT-PCR miR-107
8 [26] Northern blot, qRT-PCR miR-21
9 [27] Northern blot, qRT-PCR miR-155, miR-203, miR-210, and miR-222
10 [28] Northern blot, qRT-PCR miR-21 and miR-221
11 [29] Northern blot, qRT-PCR miR-10a
12 [30] qRT-PCR, luciferase assay miR-214
enough for meta-analysis by MAGIA; therefore they have
been excluded fromnetwork analysis. By theway upregulated
miRNAs which have been described as oncogenes are more
suitable for gene therapy and considered as biomarkers.
Expression profile ofmost significantly overrepresentedmiR-
NAs that were used formiRNAsmatrices in pancreatic cancer
was indicated in Table 1. There were also 1176 genes from
some overlap data to deviated outlying data, with lower
expression compared to normal condition. As miRNAs tend
to downregulate target mRNAs, these types of genes entered
into mRNA matrices. Note that information of each matrix
includes normal condition and pancreatic cancer condition.
After analyzing and matching matrices by varied algorithms,
it was determined that many of miRNAs and mRNAs had
no target and matching 𝑃 value was more than 0.05 in many
of them. Finally, 15 types from 56 miRNAs and 217 types of
target genes, whose 𝑃 values were less than 0.05, were placed
in the network.
4.2. miRNA-mRNA Network Analysis. Figure 1 shows the
miRNA-mRNA interaction network and mRNA targets of
differentially expressed miRNAs in pancreatic cancer that
have been evaluated by gene networking tools (MAGIA
and Cytoscape). This network consists of 217 nodes for
mRNA, 15 nodes for miRNA, and 241 edges that show 241
regulations between 15 miRNAs and 217 genes. The miRNAs
are presented in green circle while other circles offer for
mRNAs that are existing in yellow, orange, brick red, and
red based on the number of their regulating miRNAs. In this
network, all edges of miRNAs (green circle) tend to mRNAs
(circles by other colors), because miRNAs regulate mRNAs.
If you zoom in Figure 1, you will find more details regarding
network. Generally, when the colors tend to be red from
yellow, the numbers of interactions increase. Yellow color
represents one interaction while orange color represents two;
brick red color, three; and red color, four interactions. On
the other hand, 𝑃 values of some of mRNA, which were
assigned to their interaction with miRNAs, were more than
0.05. Therefore, they did not enter network. According to
this network 197 target genes from 217 are regulate by four
miRNAs.
4.3. Target Gene Analysis in Pancreatic Cancer. GeneCards
is a searchable, combined, database of human genes that
provides concise genomic related information, on all known
and expected human genes. A portion of the GeneCards is
related to the “Gene Associated with Disease” that represents
proven roles of each gene in various diseases based on
studies that have been done to date. GeneCards information
displayed 20 of 217 expressional genes in interaction with
fifteen miRNAs in the network which have had a permanent
role in cancer of pancreas. We also have benefited Malacard
site to understand how much every 20 genes are affective.
Malacard score is sign of relationship of this gene to pancreas
cancer that are presented in Table 2. Represented score in this
site equals the rank of GenDecks𝑃 value and gene-associated
score, multiple by the product of the logs of the ranks in
gene cards search hit scores for each of genes. In addition
to these 20 genes, the roles of 54 genes in this network are
approved in other cancers especially gastrointestinal cancer.
Therefore, 74 genes of 217 genes in the network are approved
genes regarding cancer.
Moreover, mRNAs that are targeted with more than one
miRNA are listed in Table 3. This list describes some of
the most notable genes and interactions between miRNAs
and target genes in pancreatic cancer. According to these














































































































































Figure 1: Interaction network of mRNAs and upregulated miRNAs in pancreatic cancer based on Cytoscape 3 software. Green circles shower
miRNAs and other circles offer for mRNAs that are existing in yellow, orange, brick red, and red based on the number of their regulating
miRNAs. When the colors tend to be red from yellow, the numbers of interactions increase. Yellow color represents one interaction. It means
mRNA is controlled and regulated by miRNA. Orange color represents two interactions; brick red color, three interactions; and red color,
four interactions and regulate by four miRNAs. Length edges are log 𝑃 value. (If you zoom in the figure, you will find more details regarding
network.)
findings, our network revealed that ACVR2B, GFRA1, and
MTHFR are the most gene transcripts that are regulated by
miRNAs and their relationships to pancreatic cancer were
confirmed previously. The importance of mentioned three
target genes rather than others is that they are shared inTables
2 and 3. These findings revealed that genes which are known
specifically for cancer of pancreas (Table 2) are regulated
by more than one miRNA under pancreas cancer condition
(Table 3). In other words, there is a specific control on expres-
sion of these three genes in deployment of pancreatic cancer.
There are other genes in this network that are controlled
and regulated by more than one miRNA (Table 3). However,
their role has not been studies clearly in pancreatic cancer.
In addition, miR-24, miR-210, miR-221, and miR-222 are
the most important among miRNAs. According to Figure 1,
many of existing mRNAs in the networks are controlled
and regulated by these four miRNAs. The important one
is miR-24. Because many of target genes represented in
Tables 2 and 3 are controlled and regulated by this type of
miRNA.
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Table 2: Genes in association with pancreatic cancer are shown in
the network.
Number Target gene Malacard score microRNA 𝑃 value
1 ARL4C 16.286 miR-181b 0.01238






4 SMAD2 12.814 miR-24 0.02287
5 ABCC5 12.387 miR-210 0.0 866
6 GFRA1 12.056 miR-221 0.01184
12.056 miR-210 0.04776
7 CASP2 11.982 miR-24 0.02298
8 PTPN11 10.469 miR-24 0.0054
9 PPARA 10.283 miR-222 0.04031
10 CD34 10.128 miR-24 0.00764
11 PGR 9.519 miR-24 0.02159
12 LLGL1 8.843 miR-24 0.01736
13 MTHFR 8.68 miR-103 0.04494
8.68 miR-107 0.03749
14 SLC36A1 8.592 miR-24 0.01746
15 SPNS2 8.015 miR-24 0.02632
16 TGFBR2 7.987 miR-181d 0.03812
17 PODXL 7.57 miR-221 0.01018
18 HIPK2 7.531 miR-24 0.02163
19 GNE 7.457 miR-24 0.01318
20 TCF3 7.151 miR-24 0.01106
5. Gene Ontology Annotation
GO annotation strategies also permit the functional anno-
tation of candidate genes that were uniquely downregulated
in pancreatic cancer. In Table 4, gene ontology (GO) anno-
tations for predicted target mRNAs in miRNA-mRNA inter-
action network were determined by DAVID and GeneDecks.
In view of phenotype, the miRNA target genes of the current
network are organized in three groups mortality/aging (50
genes), growth/size (42 genes), and behavior/neurological
(36 genes). Genes were predominantly grouped into func-
tional classes of protein binding (63 genes), sequence-specific
DNA binding transcription factor activity (19 genes), and
zinc ion binding (20 genes) (Table 4). The most important
biological processes are transcription, DNA-dependent, and
smoothened signaling pathway. Cellular constituents of genes
mainly belong to the cytoplasm, nucleolus, and nucleus. This
term denote the place of activity of a gene product. The
evolutionary domains ofmiRNAs target genes products in the
presented network are Ser/Thr-kinase-AS, PHF, Prot-kinase-
cat-dom, Znf-PHD-finger, Kinase-like-dom, and Znf-PHD.
6. Discussion
In our study, we used system biology tools and high-
throughput experiment data (expression profiles mRNA/
miRNA from literatures) to analyze the interaction of miR-
NAs with mRNAs that are targeted by them and are involved
in cancer of pancreas. In complex diseases like cancer the
function of genes deregulate in overlapping pathways. Tumor
cells use preexisting pathways in altered ways and they
combine components of these pathways in an innovative
way. The relevance of miRNAs in pancreatic cancer and its
therapy is now under intense investigation [12, 32]. Individual
miRNAs can target multiple mRNAs genes that are involved
in self-organization and homeostasis of living organisms.
Analyzing the network of gene-expression data make known
the organizational of gene expression and recognize new
potential drug targets in cancer.
This study has determined that 197 of 217 genes are
targeted and downregulated by only four of the miRNAs:
miR-24, miR-210, miR-221, and miR-222 in which miR-24
was the most important because numerous target genes,
represented in Tables 2 and 3, are controlled and regulated
by miR-24. This miRNA suppresses the expression of tumor
suppressor genes and cell cycle control genes by targeting the
3󸀠-UTR of their mRNA [33]. Moreover miR-210, miR-221,
and miR-222 were significantly proficient to regulate more
than one target gene which were associated with pancre-
atic cancer in this network. Remarkably, many of miRNAs
which in previous studies were significantly and specifically
determined had no target in this network. Indeed, large
amount of related genes to pancreatic cancer in published
studies not to be found in this network revealed they are
not regulated by any of 56 types of candidate miRNAs.
MTHFR, GFRA1, and ACVR2B were recognized as the most
important controlled genes in present network. We showed
that ACVR2B (Activin A receptor, type IIB) gene linked
to four types of miRNA and regulated many physiologic
and pathobiology processes including immunosuppression,
carcinogenesis, insulin secretion, and pancreas development
[34]. The expression pattern and mutations of ACVR2B has
been approved in previous studies [34, 35]. Moreover, GFRA1
(GDNF family receptor alpha-1) is a potent neurotrophic
factor that plays a key role in the control of neuron survival
and differentiation. Somewhere, this gene is introduced as a
function of age [36]. Also, MTHFR (methylenetetrahydro-
folate reductase) was proposed to participate in metabolic
pathway. One carbon pool is provided by foliate implicated
in blood circulation, cellular amino acid metabolic process,
methionine biosynthetic process, and oxidation reduction
[37]. Association of these target genes with the pathophys-
iology of pancreatic cancer has been already validated [32,
38]. Indeed their functional roles are explained by biological
process, molecular function, and cellular component GO
annotations. In eukaryotic cells, GO annotations of related
proteins to target genes revealed several processes through
their domains that carry out diverse molecular functions
and participate inmultiple alternative interactions with other
proteins, organelles, or locations in the cell
(Table 4).
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Table 3: Genes target that are regulated with more than one microRNA and are displayed in the network.
Number Target gene Description GO annotation microRNAs 𝑃 value














3 C22orf29 Chromosome 22 open readingframe 29
























GDNF family receptor alpha 1;
development of EGFR signaling
pathway and axon guidance
Integrin binding and receptor binding hsa-miR-221hsa-miR-210
0.011847
0.04776
7 GPR107 G protein-coupled receptor 107 hsa-miR-222hsa-miR-221
0.012316
0.037447
8 HOOK3 Hook microtubule-tetheringprotein 3
Attach to microtubule, and more divergent


















11 MTHFR∗ Methylenetetrahydrofolatereductase (NAD(P)H)
Methylenetetrahydrofolate reductase






12 N4BP1 NEDD4 binding protein 1 Protein binding hsa-miR-222hsa-miR-221
0.001158
0.003722
13 NXF1 Nuclear RNA export factor 1
Nucleocytoplasmic transporter activity and
nucleotide binding
mRNA processing and transport of mature









containing, family M, and
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16 TSPAN14 Tetraspanin 14 hsa-miR-24 0.000255
hsa-miR-210 0.01834
17 UBN2 Ubinuclein 2 hsa-miR-24 0.005656
hsa-miR-222 0.013163
18 ZBTB42 Zinc finger and BTB domaincontaining 42






∗Target gene that are common on Tables 2 and 3.
We confess that many of obtained outputs of high-
throughput experiments do not exist in this network any-
more. The reason of such different gene expression pro-
files from experimental studies of pancreatic cancer is that
there was no study simultaneous to analysis of miRNAs
and mRNAs in the same condition. Moreover, considering
cognitive world of transcriptomic and regulating factors, it is
not expected that miRNAs act just as regulator of mRNAs,
because new findings show that target of some miRNAs is
long noncoding RNA (lncRNAs). In addition, expressions
of many RNAs are controlled by other regulating factors
instead of miRNAs. However, according to this matter that
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Table 4: GO: discovered categories for the target genes that participate in microRNAs-mRNAs interactions in pancreatic cancer.
Attribute Descriptor Number of genes 𝑃 value
Phenotype
Mortality/aging 50 2.71𝐸 − 07
Growth/size phenotype 42 4.43𝐸 − 07
Behavior/neurological phenotype 36 8.64𝐸 − 07
GO: molecular function
Protein binding 63 3.58𝐸 − 07
Sequence-specific DNA binding transcription factor activity 19 2.01𝐸 − 06
Zinc ion binding 20 3.56𝐸 − 05
GO: cellular component
Cytoplasm 56 1.43𝐸 − 09
Nucleolus 30 1.03𝐸 − 08
Nucleus 59 4.66𝐸 − 08
GO: biological process Transcription, DNA-dependent 32 2.34𝐸 − 08
Smoothened signaling pathway 5 1.72𝐸 − 05
Domain
Ser/Thr kinase AS 11 3.29𝐸 − 06
PHF 6 7.42𝐸 − 06
Prot kinase cat dom 13 8.79𝐸 − 06
Znf PHD-finger 6 1.48𝐸 − 05
Kinase-like dom 13 2.03𝐸 − 05
Znf PHD 6 2.73𝐸 − 05
more than 60% of expressions of protein producer genes in
human are regulated by miRNAs and this fact that the more
important and famous regulating mechanism for expression
genes are miRNAs, one of scientists’ purposes is studying and
controlling them under different circumstances.
7. Conclusion
Previous works investigated just expression of miRNAs or
mRNAs related to pancreatic cancer that are a rich treasury
of information. They are possible to achieve to biomarkers.
However, by drawing connecting networks, it leads us to
the main passkeys in regard to the relationship between
miRNAs andmRNAs in occurrence or development of cancer
under certain conditions. We demonstrate bioinformatics
approach to study the key communication between mRNAs
and miRNAs. The obtained results of this network revealed
that 217 mRNA were significantly regulated by 15 miRNAs
in pancreatic cancer. The miR-24 has been reported as most
important miRNA and genes such as ACVR2B, GFRA1, and
MTHFR are most involved in pancreatic cancer. Therefore
this study provides new opportunities for studying novel
molecular pathways of pancreatic cancer pathogenesis and
for developing new therapeutic approaches.
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